New scan may replace costly imaging for prostate cancer patients
NCT ID NCT06828263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a special type of scan (LuPSMA-SPECT/CT) can tell doctors early if a targeted radiation therapy is working in men with advanced prostate cancer that no longer responds to hormone therapy. About 130 participants will be followed to see if changes on the scan match how long they live. If successful, this could replace more expensive PET scans and help doctors switch treatments sooner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Grenoble Alpes
RECRUITINGGrenoble, 38053, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glow-in-the-dark dye may help surgeons spot hidden prostate cancer cells
- Radiation zaps prostate cancer spots in men not helped enough by hormone drugs
- New Imaging-Guided combo therapy aims to slow prostate cancer spread
- Could a special PET scan spot returning prostate cancer sooner?
- Lab-Grown Mini-Tumors could predict best prostate cancer therapy
- Could a common ED drug shield prostate cancer patients from chemo nerve pain?